NY-ESO-1 is an important ovarian cancer antigen and Golnik et al observed that NY-ESO-1 antigen presentation is only weakly inhibited by RPN13 knockdown, whereas RPN10 knockdown profoundly inhibited it [35]. Here, ADRM1 is linked to ovarian carcinoma.